EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma

EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma

Source: 
BioPharma Dive
snippet: 

The European Medicines Agency is considering advising doctors to more closely monitor patients treated with Novartis’ gene therapy Zolgensma for liver injury, according to a notice put out Friday.